CytoSorbents Rights Offering Begins

Rights Offering Details - CytoSorbents Corporation announces the commencement of its Rights Offering, with stockholders and certain warrantholders of record on December 16, 2024, receiving one non-transferable Subscription Right Warrant per share of common stock owned [1] - Each Subscription Right allows the purchase of one Unit at a subscription price of $1 00 per Unit, with each Unit consisting of one share of common stock and two transferable short-term Right Warrants to purchase up to two additional shares of common stock at discounted prices [2] - The Subscription Rights must be exercised before the expiration date of 5 00 PM EST on January 10, 2025, and investors can exercise all, some, or none of their Subscription Rights through online or hard copy documentation or by contacting their broker or banking representative [2] - Investors who exercise all of their basic subscription rights may participate in an oversubscription of unsubscribed Subscription Rights, if available, and must elect this option at the time of their subscription rights exercise [2] - Upon completion of the subscription period on January 10, 2025, participating stockholders who purchased Units will receive the associated shares of common stock and Right Warrants to their brokerage account, subject to pro-rata adjustment if the Rights Offering is oversubscribed [2] Company Overview - CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification, utilizing proprietary blood purification technologies based on biocompatible, highly porous polymer beads [7] - The company's technologies are used in broad applications, including the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and the removal of inflammatory agents in critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis [7] - CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in 76 countries worldwide, with over a quarter million devices used cumulatively to date [8] - CytoSorb has received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure, to reduce pro-inflammatory cytokine levels, but is not yet approved in the United States [8] - In the U S and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, which has received two FDA Breakthrough Device Designations and is under review for marketing approval in the U S and Canada [9] Additional Information - The Rights Offering is being made pursuant to CytoSorbents' effective shelf registration statement on Form S-3 and a related prospectus supplement filed with the SEC [5] - A short presentation on the Rights Offering has been filed with the SEC as a free writing prospectus and can be found on the company's investor relations website [4] - Moody Capital Solutions, Inc is the dealer manager for the offering, and any interested broker-dealers may contact Moody at info@moodycapital com [4] - For any questions or further information about the Rights Offering, investors can contact D F King & Co , Inc , the information agent for the offering, at (800) 549-6864 or (212) 269-5550, or email CTSO@dfking com [3]